

**Development of Immediate and Sustained-release  
Formulations of the GLP-1 Receptor Agonist Exenatide  
for the Treatment of Patients with Type 2 Diabetes**

**Mark Stephen Fineman**

*Financial support provided by Amylin Pharmaceuticals, Inc. (San Diego, California USA)  
and Eli Lilly & Co (Indianapolis, Indiana USA).*

**ISBN/EAN:** 978-94-91211-87-4.

**Layout:** Bob Kielstra, Ipskamp Drukkers B.V., Enschede

**Cover design:** Brian Dangel  
Alice Izzo

**Printed by:** Ipskamp Drukkers B.V., Enschede